Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

Research & Selected Publications

HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Authors:

Yamamoto N, Dobersch S, Loveless I, one or more additional authors omitted Fields RC, one or more additional authors omitted Kugel S

Journal & Year:

Clin Cancer Res | 2025

Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages
Authors:

Iglesia MD, Jayasinghe RG, Chen S, one or more additional authors omitted Fields RC, one or more additional authors omitted Ding L

Journal & Year:

Nat Cancer | 2024

Tumour evolution and microenvironment interactions in 2D and 3D space
Authors:

Mo CK, Liu J, Chen S, one or more additional authors omitted Fields RC, one or more additional authors omitted Ding L

Journal & Year:

Nature | 2024

Treatment resistance to melanoma therapeutics on a single cell level
Authors:

Yao L, Krasnick BA, Bi Y, one or more additional authors omitted Fields RC

Journal & Year:

Sci Rep | 2024

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis
Authors:

White BS, Woo XY, Koc S, one or more additional authors omitted Fields RC, one or more additional authors omitted Chuang JH

Journal & Year:

Cancer Res | 2024

Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer
Authors:

Belle JI, Sen D, Baer JM, one or more additional authors omitted Fields RC, one or more additional authors omitted DeNardo DG

Journal & Year:

Cancer Discov | 2024

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Authors:

Swetter SM, Johnson D, Albertini MR, one or more additional authors omitted Fields RC, one or more additional authors omitted Espinosa S

Journal & Year:

J Natl Compr Canc Netw | 2024

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
Authors:

Bulle A, Liu P, Seehra K, one or more additional authors omitted Fields RC, one or more additional authors omitted Lim KH

Journal & Year:

Nat Commun | 2024